RNA Aptamer Technology

作者: Mukund Joshi , Kuldip Singh Sodhi , Rajesh Pandey , Jasbir Singh , Subhash Goyal

DOI:

关键词:

摘要: Article history Aptamers are single stranded nucleic acids that specifically recognize and bind tightly to their cognate targets due stable three dimensional structures. Nucleic acid aptamers have been developed for various applications, including diagnostics, molecular imaging biomarker discovery along with target validation, therapeutics, drug delivery. Since its in the early 1990s, aptamer technology has progressed tremendously. Automated selection procedures now allow rapid identification of DNA RNA sequences can a broad range extra intracellular proteins nanomolar affinities high specificities. The unique binding properties acids, which amenable modifications, make perfectly suitable different areas biotechnology. represent an emerging class pharmaceuticals great potential targeted cancer diagnostics therapy. Several cell-surface antigens affinity specificity described. However, clinical yet be realized demand diagnostic assays assist management existing diseases is increasing, could potentially fulfill recognition needs those assays. Compared bellwether antibody technology, research still infancy, but it progressing at fast pace. may near future form aptamer-based products market. In such products, play key role either conjunction with, or place antibodies. It also likely formats change according need better harness features. This review summarizes as valuable tools discovery, even therapeutic approaches.

参考文章(46)
Kristina W Thiel, Paloma H Giangrande, Intracellular delivery of RNA-based therapeutics using aptamers. Therapeutic Delivery. ,vol. 1, pp. 849- 861 ,(2010) , 10.4155/TDE.10.61
Shashi Kumar Srinivasan, Patrick Iversen, Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. Journal of Clinical Laboratory Analysis. ,vol. 9, pp. 129- 137 ,(1995) , 10.1002/JCLA.1860090210
C.-h. B. Chen, G. A. Chernis, V. Q. Hoang, R. Landgraf, Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 100, pp. 9226- 9231 ,(2003) , 10.1073/PNAS.1332660100
Josephine Charlton, Joseph Sennello, Drew Smith, In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase Chemistry & Biology. ,vol. 4, pp. 809- 816 ,(1997) , 10.1016/S1074-5521(97)90114-9
Daniela Castanotto, John J. Rossi, The promises and pitfalls of RNA-interference-based therapeutics Nature. ,vol. 457, pp. 426- 433 ,(2009) , 10.1038/NATURE07758
Fernando Pastor, Despina Kolonias, Paloma H. Giangrande, Eli Gilboa, Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay Nature. ,vol. 465, pp. 227- 230 ,(2010) , 10.1038/NATURE08999
P. Keck, S. Hauser, G Krivi, K Sanzo, T Warren, J Feder, D. Connolly, Vascular permeability factor, an endothelial cell mitogen related to PDGF Science. ,vol. 246, pp. 1309- 1312 ,(1989) , 10.1126/SCIENCE.2479987
Na Li, Hong Hanh Nguyen, Michelle Byrom, Andrew D. Ellington, Inhibition of Cell Proliferation by an Anti-EGFR Aptamer PLOS ONE. ,vol. 6, ,(2011) , 10.1371/JOURNAL.PONE.0020299
E. W.M NG, A. P ADAMIS, Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases Annals of the New York Academy of Sciences. ,vol. 1082, pp. 151- 171 ,(2006) , 10.1196/ANNALS.1348.062
Judy Ruckman, Louis S. Green, Jim Beeson, Sheela Waugh, Wendy L. Gillette, Dwight D. Henninger, Lena Claesson-Welsh, Nebojsa Janjic, 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) INHIBITION OF RECEPTOR BINDING AND VEGF-INDUCED VASCULAR PERMEABILITY THROUGH INTERACTIONS REQUIRING THE EXON 7-ENCODED DOMAIN Journal of Biological Chemistry. ,vol. 273, pp. 20556- 20567 ,(1998) , 10.1074/JBC.273.32.20556